Hosted on MSN24d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mDaiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo ... ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3 ...
Daiichi Sankyo ... The DXd ADC portfolio currently consists of Enhertu, a HER2 directed ADC, and Datroway, a TROP-2 directed ADC, which are being jointly developed and commercialized globally with ...
Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...
Daiichi Sankyo ... HER2 directed ADC, and DATROWAY, a TROP-2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a ...
TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo ... directed ADC, and DATROWAY, a TROP-2 directed ADC, which are being jointly developed and commercialized globally with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback